{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T06:55:06Z","timestamp":1783234506084,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTB), nontuberculous mycobacteria infections (NTM), and <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia (PJP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012\u20132016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n\u2009=\u200995 [55 incident cases]); MTB (n\u2009=\u2009100 [58]); NTM (n\u2009=\u200982 [50]); and PJP (n\u2009=\u2009100 [84]). PPVs ranged from 67.4\u201370.5% (HZ), 67.0\u201390.0% (MTB), 18.3\u201363.4% (NTM), and 20.0\u201345.0% (PJP) for prevalent cases, and 69.1\u201370.9% (HZ), 58.6\u201387.9% (MTB), 10.0\u201356.0% (NTM), and 22.6\u201351.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08466-8","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:02:11Z","timestamp":1696338131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan"],"prefix":"10.1186","volume":"23","author":[{"given":"Ryota","family":"Hase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"de Luise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Nonnenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takakazu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyo","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadao","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonobu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soko","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"8466_CR1","unstructured":"World Health Organization. Global health estimates: leading causes of death 2000\u20132019. 2020. https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-leading-causes-of-death. Accessed 1 Jul 2022."},{"key":"8466_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-018-0268-8","volume":"9","author":"S Imafuku","year":"2019","unstructured":"Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, J\u00e9gou C, et al. Burden of herpes zoster in the Japanese population with immunocompromised\/chronic disease conditions: results from a cohort study claims database from 2005\u20132014. Dermatol Ther (Heidelb). 2019;9:117\u201333.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"8466_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","volume":"20","author":"C Mu\u00f1oz-Quiles","year":"2020","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, D\u00edez-Domingo J, Orrico-S\u00e1nchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014. BMC Infect Dis. 2020;20:905.","journal-title":"BMC Infect Dis"},{"key":"8466_CR4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","volume":"190","author":"M Sester","year":"2014","unstructured":"Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168\u201376.","journal-title":"Am J Respir Crit Care Med"},{"key":"8466_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1086\/313792","volume":"30","author":"TT Yoshikawa","year":"2000","unstructured":"Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30:931\u20133.","journal-title":"Clin Infect Dis"},{"key":"8466_CR6","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.","journal-title":"BMJ Open"},{"key":"8466_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2334-13-170","volume":"13","author":"S Pinchinat","year":"2013","unstructured":"Pinchinat S, Cebri\u00e1n-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.","journal-title":"BMC Infect Dis"},{"key":"8466_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12879-017-2198-y","volume":"17","author":"LK Chen","year":"2017","unstructured":"Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017;17:213.","journal-title":"BMC Infect Dis"},{"key":"8466_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2188\/jea.JE20140210","volume":"25","author":"Y Takao","year":"2015","unstructured":"Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomi Y, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol. 2015;25:617\u201325.","journal-title":"J Epidemiol"},{"key":"8466_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/003335491012500611","volume":"125","author":"MS Calderwood","year":"2010","unstructured":"Calderwood MS, Platt R, Hou X, Malenfant J, Haney G, Kruskal B, et al. Real-time surveillance for tuberculosis using electronic health record data from an ambulatory practice in eastern Massachusetts. Public Health Rep. 2010;125:843\u201350.","journal-title":"Public Health Rep"},{"key":"8466_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1047-2797(99)00011-3","volume":"9","author":"MJ Trepka","year":"1999","unstructured":"Trepka MJ, Beyer TO, Proctor ME, Davis JP. An evaluation of the completeness of tuberculosis case reporting using hospital billing and laboratory data; Wisconsin, 1995. Ann Epidemiol. 1999;9:419\u201323.","journal-title":"Ann Epidemiol"},{"key":"8466_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pds.2049","volume":"20","author":"KL Winthrop","year":"2011","unstructured":"Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf. 2011;20:229\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8466_CR13","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3201\/eid1008.031075","volume":"10","author":"DS Yokoe","year":"2004","unstructured":"Yokoe DS, Coon SW, Dokholyan R, Iannuzzi MC, Jones TF, Meredith S, et al. Pharmacy data for tuberculosis surveillance and assessment of patient management. Emerg Infect Dis. 2004;10:1426\u201331.","journal-title":"Emerg Infect Dis"},{"key":"8466_CR14","doi-asserted-by":"crossref","unstructured":"Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86:1146-53.","DOI":"10.4065\/mcp.2011.0305"},{"key":"8466_CR15","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/MIB.0b013e3182802a9b","volume":"19","author":"MD Long","year":"2013","unstructured":"Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1018\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"8466_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/pds.5263","volume":"30","author":"C de Luise","year":"2021","unstructured":"de Luise C, Sugiyama N, Morishima T, Higuchi T, Katayama K, Nakamura S, et al. Validity of claims-based algorithms for selected cancers in Japan: results from the VALIDATE-J study. Pharmacoepidemiol Drug Saf. 2021;30:1153\u201361.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8466_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"key":"8466_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","volume":"51","author":"K Nakashima","year":"2018","unstructured":"Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2018;51:810\u201320.","journal-title":"J Microbiol Immunol Infect"},{"key":"8466_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.1471","volume":"17","author":"International Society of Pharmacoepidemiology","year":"2008","unstructured":"International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8466_CR20","unstructured":"Council for International Organizations of Medical Sciences. International ethical guidelines for epidemiological studies. 2009. https:\/\/cioms.ch\/publications\/product\/international-ethical-guidelines-for-epidemiological-studies\/. Accessed 1 Jul 2022."},{"key":"8466_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12890-020-01304-6","volume":"20","author":"S Uno","year":"2020","unstructured":"Uno S, Asakura T, Morimoto K, Yoshimura K, Uwamino Y, Nishimura T, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med. 2020;20:262.","journal-title":"BMC Pulm Med"},{"key":"8466_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5217\/ir.2021.00154","volume":"21","author":"K Matsuoka","year":"2023","unstructured":"Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res. 2023;21:88\u201399.","journal-title":"Intest Res"},{"key":"8466_CR23","unstructured":"Electronic Medicines Compendium. Atovaquone\/proguanil hydrochloride 250\u00a0mg\/100\u00a0mg film-coated tablets. 2017. https:\/\/www.medicines.org.uk\/emc\/product\/9902\/smpc. Accessed 1 Jul 2022."},{"key":"8466_CR24","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.chest.2020.05.558","volume":"158","author":"A Ghembaza","year":"2020","unstructured":"Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest. 2020;158:2323\u201332.","journal-title":"Chest"},{"key":"8466_CR25","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1\u2013ii64.","journal-title":"Thorax"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08466-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T08:02:53Z","timestamp":1701331373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08466-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8466"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08466-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Independent Ethics Committee and the Institutional Review Boards at Japanese Red Cross Narita Hospital and Kameda Medical Center approved the study protocol. The study was conducted in accordance with accepted practices for pharmacoepidemiology studies issued by the International Society for Pharmacoepidemiology [] and the Council for International Organizations of Medical Sciences []. Patients identified in the claims databases were not required to provide consent and could opt-out from participating in the study. As this study was a cross-sectional review using de-identified claims data and medical records without invasive procedures and interventions that did not use samples from human participants, written or oral informed consent was waived by the Institutional Review Boards of Japanese Red Cross Narita Hospital and Kameda Medical Center. This study used an opt-out approach to guarantee opportunities for study participants to obtain disclosed information and to refuse to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.H., E. N., T.H., M.K., S.J., and T.M. have received consultancy fees from Pfizer Inc in connection with this study. D.S. has received consultancy fees from Pfizer Inc in connection with this study and is currently affiliated with the Department of Infectious Diseases, Anjo Kosei Hospital, Anjo, Aichi, Japan. K.K. has received consultancy fees from Pfizer Inc in connection with this study and is currently affiliated with the Faculty of Informatics, Gunma University, Maebashi, Gunma, Japan. H.C. has received funding from Pfizer Inc in connection with this study through her university and has received funding from the Cystic Fibrosis Foundation, National Institute of Health, and Pfizer Inc. C.D. and N.S. are employees of Pfizer Inc. Y.T. has received speaker fees and\/or honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Mitsubishi Tanabe Pharma, and Pfizer Inc; and research grants from AbbVie, Asahi Kasei, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Eisai, and Takeda. S.S. has received consultancy fees from Pfizer Inc in connection with this study and has received funding from Bristol Myers Squibb, the Cystic Fibrosis Foundation, Janssen, National Institute of Health, PCORI, Pfizer Inc, and Pfizer Japan Inc, and personal consulting fees from Daiichi Sankyo, Janssen, Medtronic, Merck, and Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"653"}}